Personalized Medicine Diagnostic Market - PowerPoint PPT Presentation

About This Presentation
Title:

Personalized Medicine Diagnostic Market

Description:

The report provides value and growth of the global personal therapeutics market from 2017-2021. Also historic figures back to 2014 are given to illustrate growth. As the personal targeted therapeutics market is part of the overall personalized medicine market, the companion diagnostics market is also included in the report – PowerPoint PPT presentation

Number of Views:107
Slides: 11
Provided by: bharatbookseo

less

Transcript and Presenter's Notes

Title: Personalized Medicine Diagnostic Market


1
PersonAalized Medicine Diagnostic Market
  • www.bharatbook.com

2
This is a comprehensive account of the market
size, segmentation, key players, SWOT analysis,
influential technologies, and business and
economic environments. The report is supported by
over 360 tables figures over 397 pages. The
personalized medicine (global USA) market is
presented as follows   This detailed report is
supported with 360 figures and tables over 397
pages and profiles the main pharmacies in
personalized medicine.
3
(No Transcript)
4
Executive Summary
The companion diagnostic and targeted therapeutic
submarkets of the personalized medicine industry
were worth 113 billion in 2016, and will hit
over 162 billion by 2021 with a CAGR of 8.74.
The total personalized therapeutic market, for
all indications, will be worth billion by 2021,
with a CAGR of . Currently it is estimated that
the companion diagnostic segment is worth
billion globally, mainly coming from oncology,
cardiovascular and infectious disease (HIV/HCV)
tests. This is set to rise vertically over the
next five years and by 2021 will be worth over
billion, with a CAGR of .
5
This study details a comprehensive financial and
strategic review of key players in the
personalized medicine industry. Significant
drivers and restraints of this market are
revealed and market opportunities and challenges
are identified. Disruptive technologies that are
propelling the personalized medicine and
companion diagnostic market are scrutinized. It
examines the current genetic diagnostic tests and
companion diagnostic assays that are in use by
the medical and pharmaceutical industry today.
6
Current developments in personalized medicine and
the pharmacogenomics revolution are discussed.
The emerging trends that appear in key markets
such as the US, UK, Germany and France are
elucidated and analyzed. This study reveals
market figures of the overall personalized
medicine market and also sub-markets figures with
respect to companion diagnostics, targeted cancer
therapeutics, medical technologies,
pharmacogenomics, consumer genomics, molecular
diagnostics and liquid biopsies. Specific
indication markets are also included such as
cancer, cardiovascular and infectious disease.
7
The report provides value and growth of the
global personal therapeutics market from
2017-2021. Also historic figures back to 2014 are
given to illustrate growth. As the personal
targeted therapeutics market is part of the
overall personalized medicine market, the
companion diagnostics market is also included in
the report The report goes into detail regarding
different indications, mainly oncology drugs as
these hold most market share, and also
cardiovascular and infectious disease markets.
It contains specific data for both the targeted
therapeutic and companion diagnostic sections of
the personalized medicine market.
8
Targeted Cancer Therapeutics
Targeted cancer therapeutic sales have
significantly risen in the recent past with a x
increase from 2013 to 2014 alone. The global
oncology market is currently booming and one of
the main reasons for this increase is the
dramatic rise in the number of prescribed
targeted therapies. The market is also growing in
size as the cost of targeted therapeutics is
high. This is due to longer treatment times,
increased investment and development costs.
Targeted therapeutics also are, by definition,
designed to treat smaller cohorts of patients,
albeit more effectively. Therefore, pharmacys
need to recoup costs via pricing.
9
Two major targeted therapeutics on the market are
Roches melanoma agent Zelboraf and Pfizers lung
cancer agent Xalkori. Zelboraf (vemurafenib) is a
MEK inhibitor indicated for skin cancer and in
FY2013 reached x million. Xalkori (crizotinib)
is indicated in patients positive for an ALK
mutation and has an annual sale figure of x
million.
10
More Information
Personalized Medicine Diagnostic Market
Contact us atBharat Book BureauTel 91 22
27810772 / 27810773Email poonam_at_bharatbook.comO
ur Blog https//www.bharatbook.com/blog/Twitter
https//twitter.com/researchbookFacebook
https//www.facebook.com/BharatBook3BLinkedIn
http//www.linkedin.com/company/bharat-book-bureau
Write a Comment
User Comments (0)
About PowerShow.com